AbbVie extended the patent life on Humira for years, enough time to more than replace the sales. Now Merck and Bristol Myers ...

Alvotech has five approved drugs, including biosimilars of AbbVie's Humira, Johnson & Johnson's Stelara/Simponi, and Eylea. See why ALVO stock is a Strong Buy.

AbbVie’s lost exclusivity for Humira is offset by immunology and neurology sales, diversified by its emerging oncology pipeline.

Share on Pinterest A diet high in ultra-processed foods may be linked to a higher risk of Crohn’s disease. Image Credit: wragg/Getty Images In 2019, about 4.9 million people around the world were ...

AbbVie ABBV is a dominant player in the immunology space, powered by three blockbuster drugs — Skyrizi, Rinvoq and Humira — which together account for nearly half of its top line. Although the company ...

New guidelines recommend doctors tackle Crohn's disease head-on, calling for the use of cutting-edge drugs as early as possible to quell the autoimmune GI disorder as quickly as possible. The updated ...

What Is Crohn’s Constipation? You likely have constipation if it's hard for you to poop and you're having fewer bowel movements than you normally do. The same is true whether or not you have Crohn’s ...

Mutations in a gene associated with Crohn's disease have been found to rob critical immune cells of their ability to switch modes, causing them to overreact and trigger inflammation. Variations in the ...

Hello, Toni: You helped me sign up for a Medicare Supplement Plan G and a Medicare Part D prescription drug plan; both plans started January 2021. These two plans have served me well so far. I just ...

You helped me sign up for a Medicare Supplement Plan G and a Medicare Part D prescription drug plan; both plans started . These two plans have served me well so far. I just received information that ...

UC San Diego researchers combined artificial intelligence with molecular biology to unravel how immune cells in the gut decide between inflammation and healing, a process gone awry in Crohn’s disease.